Information  X 
Enter a valid email address

Plus500 Ltd (PLUS)

  Print      Mail a friend

Monday 19 November, 2018

Plus500 Ltd

Transaction in Own Shares

RNS Number : 6912H
Plus500 Limited
19 November 2018
 

 19 November 2018

Plus500 Ltd.

("Plus500" or "the Company")

 Transaction in Own Shares

Plus500, a leading online service provider for trading Contracts for Differences ("CFDs") internationally, announces that, in accordance with the terms of its share buyback programme announced on 23 October 2018 ("Share Buyback Programme"), the Company purchased the following number of its ordinary shares of ILS 0.01 each through Liberum Capital Limited.

Date of purchase:

 16 November 2018

Aggregate number of ordinary shares of ILS 0.01 each purchased:

30,455

Lowest price paid per share (GBp):

1,264

Highest price paid per share (GBp):

1,296

Volume weighted average price paid per share (GBp):

1,274.40

 

The Company will hold the repurchased shares in treasury. Following the purchase of these shares, the remaining number of ordinary shares in issue will be 113,869,621 (excluding treasury shares), and the company will hold 1,018,756 ordinary shares in treasury. Therefore, the total voting rights in Plus500 will be 113,869,621. This figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), the table below contains detailed information of the individual trades made by Liberum Capital Limited as part of the Share Buyback Programme.

 

Individual transactions:

Number of shares purchased

Transaction price (pence per share)

Time of transaction

Venue

46

1280

16:22:18

BATE

3

1284

15:20:04

CHIX

978

1284

15:20:04

CHIX

107

1284

15:20:04

CHIX

565

1280

15:16:21

BATE

333

1280

15:16:21

BATE

211

1280

15:16:21

BATE

26

1280

15:08:43

CHIX

378

1280

15:08:43

CHIX

596

1280

15:08:43

CHIX

647

1282

15:02:20

XLON

291

1282

15:02:14

XLON

997

1277

14:45:47

CHIX

114

1274

14:39:54

XLON

333

1274

14:39:54

XLON

559

1274

14:39:54

XLON

1011

1277

14:28:22

XLON

112

1277

14:18:20

XLON

620

1277

14:15:37

XLON

301

1277

14:14:49

XLON

1073

1270

13:59:06

XLON

332

1270

13:58:00

CHIX

632

1270

13:58:00

CHIX

29

1270

13:58:00

CHIX

927

1273

13:32:49

BATE

533

1272

13:07:11

CHIX

497

1272

13:07:00

CHIX

275

1270

12:40:02

CHIX

65

1270

12:40:02

CHIX

2

1270

12:39:23

CHIX

83

1270

12:34:41

CHIX

275

1270

12:27:15

CHIX

268

1270

12:22:07

CHIX

402

1267

12:18:37

BATE

640

1264

12:05:36

CHIX

361

1264

12:03:34

CHIX

338

1265

11:51:03

BATE

115

1265

11:47:22

BATE

400

1265

11:47:10

BATE

258

1265

11:47:10

BATE

336

1267

11:30:30

BATE

7

1267

11:29:01

BATE

275

1267

11:28:17

BATE

294

1267

11:25:53

BATE

1047

1271

11:11:41

XLON

269

1266

11:11:15

CHIX

267

1265

11:08:41

CHIX

574

1275

10:37:37

CHIX

187

1275

10:30:24

CHIX

269

1275

10:27:11

CHIX

1028

1272

10:12:13

BATE

271

1269

10:09:42

XLON

1051

1270

09:52:43

CHIX

142

1274

09:32:22

XLON

966

1274

09:32:22

XLON

919

1264

09:22:09

CHIX

916

1267

09:18:34

CHIX

151

1273

09:08:10

CHIX

275

1273

09:08:03

CHIX

135

1273

09:08:02

CHIX

533

1273

09:08:02

CHIX

1062

1278

09:06:04

BATE

19

1278

08:50:00

XLON

990

1278

08:50:00

XLON

425

1282

08:42:02

CHIX

360

1282

08:39:26

CHIX

237

1282

08:39:26

CHIX

992

1292

08:36:00

CHIX

279

1289

08:34:45

CHIX

223

1296

08:19:34

XLON

112

1291

08:18:03

XLON

11

1290

08:18:03

XLON

100

1290

08:18:03

XLON

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
POSBIBDBSUBBGII

a d v e r t i s e m e n t